In Vivo CRO 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The In Vivo CRO Market size is expected to reach USD 11.71 Billion in 2034 from USD 5.40 Billion (2025) growing at a CAGR of 8.97% during 2026-2034.

The global in vivo CRO market is experiencing strong growth as pharmaceutical and biotechnology companies increasingly outsource preclinical research activities. In vivo contract research organizations conduct animal-based studies to evaluate the safety and efficacy of new drugs before clinical trials. Outsourcing these studies allows companies to access specialized expertise, advanced laboratory facilities, and regulatory compliance support.

The increasing number of drug discovery programs and the growing complexity of biological therapies are driving demand for in vivo research services. CROs provide a wide range of services including toxicology testing, pharmacokinetic studies, and disease model development. Pharmaceutical companies rely on these services to accelerate drug development timelines while maintaining high research standards. Additionally, technological advancements in imaging and biomarker analysis are improving the quality of in vivo research.

Looking forward, the market is expected to expand as the global pharmaceutical pipeline continues to grow. Increasing investment in biotechnology research and personalized medicine will create new opportunities for CRO service providers. As drug development becomes more complex and regulatory requirements become stricter, the role of specialized in vivo research organizations will become even more important.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type of Molecule

• Small Molecules
• Large Molecules

By Therapeutic Area

• Oncology
• Cardiology
• Diabetes
• Autoimmune/Inflammation Conditions
• Infectious Diseases
• CNS Conditions
• Others

By Service Type

• Preclinical Testing
• Clinical Research Services
• Laboratory Services
• Consulting Services

COMPANIES PROFILED

• IQVIA Inc, Crown Bioscience Inc, Taconic Biosciences Inc, PsychoGenics Inc, Evotec SE, Janvier Labs, Biocytogen Co Ltd, GemPharmatech Co Ltd, Charles River Laboratories International, ICON plc, Labcorp Drug Development, Parexel International Corporation, SMO Clinical Research I Pvt Ltd, WuXi AppTec Co Ltd, Syneos Health
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IN VIVO CRO MARKET: BY TYPE OF MOLECULE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type Of Molecule
• 4.2. Small Molecules Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Large Molecules Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IN VIVO CRO MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapeutic Area
• 5.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cardiology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Autoimmune/Inflammation Conditions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. CNS Conditions Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IN VIVO CRO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Service Type
• 6.2. Preclinical Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinical Research Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Laboratory Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Consulting Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IN VIVO CRO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type Of Molecule
  • 7.2.2 By Therapeutic Area
  • 7.2.3 By Service Type
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type Of Molecule
  • 7.3.2 By Therapeutic Area
  • 7.3.3 By Service Type
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type Of Molecule
  • 7.4.2 By Therapeutic Area
  • 7.4.3 By Service Type
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type Of Molecule
  • 7.5.2 By Therapeutic Area
  • 7.5.3 By Service Type
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type Of Molecule
  • 7.6.2 By Therapeutic Area
  • 7.6.3 By Service Type
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL IN VIVO CRO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 IQVIA Inc
  • 9.2.2 Crown Bioscience Inc
  • 9.2.3 Taconic Biosciences Inc
  • 9.2.4 PsychoGenics Inc
  • 9.2.5 Evotec SE
  • 9.2.6 Janvier Labs
  • 9.2.7 Biocytogen Co. Ltd
  • 9.2.8 GemPharmatech Co. Ltd
  • 9.2.9 Charles River Laboratories International
  • 9.2.10 ICON Plc
  • 9.2.11 Labcorp Drug Development
  • 9.2.12 Parexel International Corporation
  • 9.2.13 SMO Clinical Research (I) Pvt Ltd
  • 9.2.14 WuXi AppTec Co. Ltd
  • 9.2.15 Syneos Health